The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2023

Filed:

Apr. 06, 2021
Applicant:

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Laurence J N Cooper, Houston, TX (US);

Hiroki Torikai, Houston, TX (US);

Ling Zhang, Houston, TX (US);

Helen Huls, Houston, TX (US);

Feng Wang-Johanning, Bastrop, TX (US);

Lenka Hurton, Houston, TX (US);

Simon Olivares, Houston, TX (US);

Janani Krishnamurthy, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/54 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); A61P 37/00 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 35/17 (2013.01); A61K 39/00117 (2018.08); A61K 39/00119 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001129 (2018.08); A61K 39/001151 (2018.08); A61K 39/001164 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001174 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001194 (2018.08); A61P 37/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.


Find Patent Forward Citations

Loading…